$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

$eltp Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222022928 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$8.586M	$7.673M	$7.672M
YoY Change	0.32%	8.73%	74.54%
Cost Of Revenue	$4.761M	$3.675M	$4.257M
YoY Change	-0.6%	4.9%	68.3%
Gross Profit	$3.824M	$3.998M	$3.415M
YoY Change	1.49%	12.5%	83.0%
Gross Profit Margin	44.54%	52.1%	44.51%
Selling, General & Admin	$1.197M	$1.723M	$1.538M
YoY Change	28.65%	60.55%	84.1%
% of Gross Profit	31.29%	43.11%	45.03%
Research & Development	$1.227M	$955.4K	$738.8K
YoY Change	9.92%	-20.52%	-58.38%
% of Gross Profit	32.09%	23.9%	21.64%
Depreciation & Amortization	$316.0K	$296.3K	$300.8K
YoY Change	5.67%	-5.25%	-6.86%
% of Gross Profit	8.26%	7.41%	8.81%
Operating Expenses	$2.743M	$2.975M	$2.563M
YoY Change	16.96%	14.94%	-12.63%
Operating Profit	$1.081M	$1.023M	$851.7K
YoY Change	-24.0%	5.96%	-179.78%
Interest Expense	$242.8K	$216.8K	-$163.4K
YoY Change	-35.5%	372.37%	-61.88%
% of Operating Profit	22.45%	21.2%	-19.18%
Other Income/Expense, Net	$445.6K	-$716.8K
YoY Change	18.4%	-226.06%
Pretax Income	$1.527M	$305.9K	$688.3K
YoY Change	-15.13%	-80.06%	-242.62%
Income Tax	$11.59K	$0.00	-$1.740M
% Of Pretax Income	0.76%	0.0%	-252.86%
Net Earnings	$1.515M	$305.9K	$2.429M
YoY Change	-15.59%	-87.2%	-603.24%
Net Earnings / Revenue	17.65%	3.99%	31.66%
Basic Earnings Per Share	$0.00	$0.00
Diluted Earnings Per Share	$0.00	$0.00	$2.402K
COMMON SHARES
Basic Shares Outstanding	1.011B shares	1.011B shares
Diluted Shares Outstanding	1.012B shares	1.011B shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.56M	$19.78M	$8.535M
YoY Change	313.19%	316.35%	167.33%
Cash & Equivalents	$18.56M	$19.78M	$8.535M
Short-Term Investments
Other Short-Term Assets	$219.9K	$507.9K	$527.0K
YoY Change	26.66%	4.76%	6.97%
Inventory	$7.468M	$7.617M	$6.741M
Prepaid Expenses
Receivables	$4.230M	$3.965M	$3.058M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$30.47M	$31.87M	$18.86M
YoY Change	91.87%	108.07%	54.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.54M	$5.755M	$5.953M
YoY Change	43.68%	-23.73%	-13.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$91.74K	$291.7K	$91.74K
YoY Change	-74.84%	-27.97%	0.0%
Other Assets	$2.577M	$2.577M	$2.577M
YoY Change	536.26%	2709.0%	536.25%
Total Long-Term Assets	$19.87M	$16.24M	$16.29M
YoY Change	34.79%	10.65%	16.38%
TOTAL ASSETS
Total Short-Term Assets	$30.47M	$31.87M	$18.86M
Total Long-Term Assets	$19.87M	$16.24M	$16.29M
Total Assets	$50.34M	$48.11M	$35.15M
YoY Change	64.39%	60.4%	34.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.724M	$1.614M	$1.431M
YoY Change	-3.72%	-21.34%	53.92%
Accrued Expenses	$4.578M	$4.810M	$4.693M
YoY Change	14.78%	15.99%	5.26%
Deferred Revenue	$13.33K	$13.33K	$13.33K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$502.6K	$435.0K	$353.8K
YoY Change	-1.68%	-25.36%	-13.87%
Total Short-Term Liabilities	$6.843M	$7.080M	$6.694M
YoY Change	8.56%	4.19%	15.17%
LONG-TERM LIABILITIES
Long-Term Debt	$15.53M	$13.21M	$1.389M
YoY Change	954.81%	693.7%	-20.21%
Other Long-Term Liabilities		$40.55K	$38.78K
YoY Change		-98.57%	-98.44%
Total Long-Term Liabilities	$16.31M	$15.50M	$3.233M
YoY Change	327.14%	244.62%	-23.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.843M	$7.080M	$6.694M
Total Long-Term Liabilities	$16.31M	$15.50M	$3.233M
Total Liabilities	$23.15M	$22.58M	$9.927M
YoY Change	128.73%	99.93%	-1.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$138.2M	-$139.8M	-$140.1M
YoY Change
Common Stock	$1.014M	$1.011M	$1.011M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.8K	$306.8K	$306.8K
YoY Change
Treasury Stock Shares	100.0K shares	100.0K shares	100.0K shares
Shareholders Equity	$27.19M	$25.53M	$25.22M
YoY Change
Total Liabilities & Shareholders Equity	$50.34M	$48.11M	$35.15M
YoY Change	64.39%	60.4%	34.21%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$1.515M	$305.9K	$2.429M
YoY Change	-15.59%	-87.2%	-603.24%
Depreciation, Depletion And Amortization	$316.0K	$296.3K	$300.8K
YoY Change	5.67%	-5.25%	-6.86%
Cash From Operating Activities	$1.495M	-$557.5K	$1.605M
YoY Change	872.44%	-132.5%	-314.22%
INVESTING ACTIVITIES
Capital Expenditures	-$5.105M	-$94.60K	-$264.2K
YoY Change	3364.37%	1811.11%	42.88%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$5.105M	-$94.60K	-$264.2K
YoY Change	3364.37%	1811.05%	42.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.385M	$11.90M	-94.24K
YoY Change	-995.05%	-7898.45%	-92.67%
NET CHANGE
Cash From Operating Activities	1.495M	-$557.5K	1.605M
Cash From Investing Activities	-5.105M	-$94.60K	-264.2K
Cash From Financing Activities	2.385M	$11.90M	-94.24K
Net Change In Cash	-1.225M	$11.24M	1.247M
YoY Change	370.87%	621.74%	-156.17%
FREE CASH FLOW
Cash From Operating Activities	$1.495M	-$557.5K	$1.605M
Capital Expenditures	-$5.105M	-$94.60K	-$264.2K
Free Cash Flow	$6.601M	-$462.9K	$1.870M
YoY Change	2091.84%	-126.91%	-431.2%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001053369
CY2022Q2	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2022Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q2	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss		usd
CY2021Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
CY2022Q2	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1		usd
CY2022Q2	us-gaap	Stock Issued1 StockIssued1		usd
CY2022Q2	ELTP	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets		usd
CY2022Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther		usd
CY2022Q2	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2021Q2	us-gaap	Dilutive Securities DilutiveSecurities		usd
CY2022Q2	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1		usd
CY2022Q2	ELTP	Finitelived Intangible Assets Reductions FinitelivedIntangibleAssetsReductions		usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1		usd
CY2022	ELTP	Finitelived Intangible Assets Reductions FinitelivedIntangibleAssetsReductions		usd
CY2022Q1	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted During Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedDuringPeriodWeightedAverageExercisePrice
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2021Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted During Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedDuringPeriodWeightedAverageExercisePrice
CY2022Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedForfeituresAndExpirations		shares
CY2022Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Forfeitures And Expiration Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedForfeituresAndExpirationWeightedAverageExercisePrice
CY2021Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedForfeituresAndExpirations		shares
CY2021Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Forfeitures And Expiration Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedForfeituresAndExpirationWeightedAverageExercisePrice
CY2022Q2	dei	Document Type DocumentType	10-Q
CY2022Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q2	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q2	dei	Entity File Number EntityFileNumber	001-15697
CY2022Q2	dei	Entity Registrant Name EntityRegistrantName	ELITE PHARMACEUTICALS, INC.
CY2022Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3542636
CY2022Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	165 LUDLOW AVENUE
CY2022Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	NORTHVALE
CY2022Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07647
CY2022Q2	dei	City Area Code CityAreaCode	(201)
CY2022Q2	dei	Local Phone Number LocalPhoneNumber	750-2646
CY2022Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022Q2	dei	Trading Symbol TradingSymbol	ELTP
CY2022Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1011281988	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19779584	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8535357	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3965109	usd
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3057913	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	7617163	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	6741170	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	507923	usd
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	526949	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	31869779	usd
CY2022Q1	us-gaap	Assets Current AssetsCurrent	18861389	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13641313	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13348565	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5754841	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5952992	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	980871	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1031884	usd
CY2022Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2022Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	2171821	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405163	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	405039	usd
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	291738	usd
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	91738	usd
CY2022Q2	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	696901	usd
CY2022Q1	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	496777	usd
CY2022Q2	us-gaap	Assets Assets	48108248	usd
CY2022Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	100822	usd
CY2022Q1	us-gaap	Secured Debt Current SecuredDebtCurrent	100822	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	334134	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	253006	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	207373	usd
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202953	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7079757	usd
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6694241	usd
CY2022Q1	us-gaap	Assets Assets	35148898	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1614260	usd
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1430985	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4809835	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4693142	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	13333	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	28889	usd
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	32226	usd
CY2022Q2	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1143394	usd
CY2022Q1	us-gaap	Secured Long Term Debt SecuredLongTermDebt	1139848	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	12063213	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	249046	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	782232	usd
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	835893	usd
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1436980	usd
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	40551	usd
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	38780	usd
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	15495259	usd
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3232630	usd
CY2022Q2	us-gaap	Liabilities Liabilities	22575016	usd
CY2022Q1	us-gaap	Liabilities Liabilities	9926871	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1445000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1011381988	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1011381988	shares
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-139753861	usd
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140059744	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25533232	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1011281988	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1011281988	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	1011385	usd
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	1011385	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164582549	usd
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	164577227	usd
CY2022Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	100000	shares
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	306841	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48108248	usd
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35148898	usd
CY2022Q2	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	6327141	usd
CY2021Q2	ELTP	Revenue From Manufacturing Fees RevenueFromManufacturingFees	5750036	usd
CY2022Q2	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1345767	usd
CY2021Q2	ELTP	Revenue From Licensing Fees RevenueFromLicensingFees	1306753	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7672908	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7056789	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	3675061	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	3503262	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	3997847	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	3553527	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	955443	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1202192	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1718104	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1070664	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5322	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2811	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	296294	usd
CY2021Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	312702	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2975163	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	2588369	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1022684	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	965158	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-500143	usd
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	614461	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	216787	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	45893	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	129	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	42	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-716801	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	568610	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	305883	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1533768	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011381988	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1009199886	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011381988	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1009199886	shares
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	25222027	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5322	usd
CY2021Q2	us-gaap	Interest Income Expense After Provision For Loan Loss InterestIncomeExpenseAfterProvisionForLoanLoss	855350	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	2389118	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25533232	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16151929	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	2389118	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2811	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	157500	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	18701358	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	305883	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	2389118	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	296294	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	312702	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	51013	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	57530	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-500143	usd
CY2021Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	614461	usd
CY2022Q2	ELTP	Accrued Compensation Non Cash AccruedCompensationNonCash	143870	usd
CY2021Q2	ELTP	Accrued Compensation Non Cash AccruedCompensationNonCash	218808	usd
CY2022Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	5322	usd
CY2021Q2	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2811	usd
CY2022Q2	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	602	usd
CY2021Q2	ELTP	Noncash Rent Expense And Lease Accretion NoncashRentExpenseAndLeaseAccretion	567	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	907196	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-118641	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	875993	usd
CY2021Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1690615	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	180974	usd
CY2021Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-251896	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	156098	usd
CY2021Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	731566	usd
CY2022Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3337	usd
CY2021Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3333	usd
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-49241	usd
CY2021Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-59771	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-557516	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1715459	usd
CY2022Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	94597	usd
CY2021Q2	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	4950	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94597	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4950	usd
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	216787	usd
CY2022Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	12000000	usd
CY2022Q2	ELTP	Other Loan Payment OtherLoanPayment	103536	usd
CY2021Q2	ELTP	Other Loan Payment OtherLoanPayment	152549	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11896464	usd
CY2021Q2	us-gaap	Interest Paid Net InterestPaidNet	14043	usd
CY2021Q2	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	244124	usd
CY2021Q2	us-gaap	Stock Issued1 StockIssued1	157500	usd
CY2021Q2	ELTP	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	1042799	usd
CY2021Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-152549	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11244351	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1557960	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8940396	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3597781	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20184747	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5155741	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7672908	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7056789	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	305883	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1774657	usd
CY2022Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	405163	usd
CY2022Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	405039	usd
CY2022Q2	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	305883	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2389118	usd
CY2021Q2	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-614461	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1011381988	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1009199886	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1011381988	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1009199886	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	936837	usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-500143	usd
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1436980	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	397061	usd
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	159808	usd
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	23737	usd
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1203204	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	7196365	usd
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	5378158	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	7617163	usd
CY2022Q1	us-gaap	Inventory Net InventoryNet	6741170	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19396154	usd
CY2022Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	19301557	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13641313	usd
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13348565	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5754841	usd
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5952992	usd
CY2022Q2	us-gaap	Depreciation Depreciation	292748	usd
CY2021Q2	us-gaap	Depreciation Depreciation	309157	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6634035	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6634035	usd
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3750000	usd
CY2022Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3625000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414985	usd
CY2022Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	414989	usd
CY2022Q2	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	153333	usd
CY2022Q1	ELTP	Accrued Consultant Contract Fees AccruedConsultantContractFees	153333	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	usd
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	usd
CY2022Q2	ELTP	Accrued Director Dues AccruedDirectorDues	112500	usd
CY2022Q1	ELTP	Accrued Director Dues AccruedDirectorDues	90000	usd
CY2022Q2	us-gaap	Interest Payable Current InterestPayableCurrent	61300	usd
CY2022Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	56250	usd
CY2022Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	143000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	121467	usd
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	126820	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4809835	usd
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4693142	usd
CY2022Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	29467	usd
CY2022Q1	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	7367	usd
CY2022Q2	us-gaap	Loans Payable LoansPayable	12397347	usd
CY2022Q1	us-gaap	Loans Payable LoansPayable	502052	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	334134	usd
CY2022Q1	us-gaap	Loans Payable Current LoansPayableCurrent	253006	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	12063213	usd
CY2022Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	249046	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	177579	usd
CY2021Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	6109	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	42222	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2022Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	28889	usd
CY2022Q1	us-gaap	Deferred Revenue DeferredRevenue	45559	usd
CY2022Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	13333	usd
CY2022Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	32226	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Method FiniteLivedIntangibleAssetsAmortizationMethod	These line items represent the unamortized amounts of a $200,000 advance payment received for a TAGI Pharma (“TAGI”) licensing agreement with a fifteen-year term beginning in September 2010 and ending in August 2025
CY2020Q4	ELTP	Operating Lease Renewal Term OperatingLeaseRenewalTerm	The Pompano Office Lease is for approximately 1,275 square feet of office space, with Elite taking occupancy on November 1, 2020. The Pompano Office has a term of three years, ending on October 31, 2023
CY2022Q2	us-gaap	Payments For Rent PaymentsForRent	64578	usd
CY2021Q2	us-gaap	Payments For Rent PaymentsForRent	62877	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	195216	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	254050	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	243612	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	248484	usd
CY2022Q2	ELTP	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	189144	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1130506	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	140901	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	989605	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	79008661	shares
CY2022Q1	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice	0.1521
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	79008661	shares
CY2021Q1	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice	0.1521
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	79008661	shares
CY2022Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice	0.1521
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	79008661	shares
CY2021Q2	ELTP	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWeightedAverageExercisePrice	0.1521
CY2022Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y9M18D
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y1M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.14
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y9M18D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5650000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1100000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2022Q2	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAverageRemainingContractualTermGranted	P10Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13970
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6750000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.14
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y9M18D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4530001	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.16
CY2022Q2	ELTP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableOutstandingWeightedAverageRemainingContractualTerm	P2Y3M18D
CY2022Q2	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.09
CY2022Q1	ELTP	Price Difference Between Exercise Price And Quoted Price PriceDifferenceBetweenExercisePriceAndQuotedPrice	0.10
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	44330	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q2	us-gaap	Area Of Land AreaOfLand	35000	sqft

Files In Submission

Name	View Source	Status
ex10-3_018.jpg	Edgar Link	pending
0001493152-22-022928-index-headers.html	Edgar Link	pending
0001493152-22-022928-index.html	Edgar Link	pending
0001493152-22-022928.txt	Edgar Link	pending
0001493152-22-022928-xbrl.zip	Edgar Link	pending
eltp-20220630.xsd	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-2_001.jpg	Edgar Link	pending
ex10-2_002.jpg	Edgar Link	pending
ex10-2_003.jpg	Edgar Link	pending
ex10-2_004.jpg	Edgar Link	pending
ex10-2_005.jpg	Edgar Link	pending
ex10-2_006.jpg	Edgar Link	pending
ex10-2_007.jpg	Edgar Link	pending
ex10-2_008.jpg	Edgar Link	pending
ex10-2_009.jpg	Edgar Link	pending
ex10-2_010.jpg	Edgar Link	pending
ex10-2_011.jpg	Edgar Link	pending
ex10-2_012.jpg	Edgar Link	pending
ex10-2_013.jpg	Edgar Link	pending
ex10-2_014.jpg	Edgar Link	pending
ex10-2_015.jpg	Edgar Link	pending
ex10-2_016.jpg	Edgar Link	pending
ex10-2_017.jpg	Edgar Link	pending
ex10-2_018.jpg	Edgar Link	pending
ex10-2_019.jpg	Edgar Link	pending
ex10-2_020.jpg	Edgar Link	pending
ex10-2_021.jpg	Edgar Link	pending
ex10-2_022.jpg	Edgar Link	pending
ex10-2_023.jpg	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex10-3_001.jpg	Edgar Link	pending
ex10-3_002.jpg	Edgar Link	pending
ex10-3_003.jpg	Edgar Link	pending
ex10-3_004.jpg	Edgar Link	pending
ex10-3_005.jpg	Edgar Link	pending
ex10-3_006.jpg	Edgar Link	pending
ex10-3_007.jpg	Edgar Link	pending
ex10-3_008.jpg	Edgar Link	pending
ex10-3_009.jpg	Edgar Link	pending
ex10-3_010.jpg	Edgar Link	pending
ex10-3_011.jpg	Edgar Link	pending
ex10-3_012.jpg	Edgar Link	pending
ex10-3_013.jpg	Edgar Link	pending
ex10-3_014.jpg	Edgar Link	pending
ex10-3_015.jpg	Edgar Link	pending
ex10-3_016.jpg	Edgar Link	pending
ex10-3_017.jpg	Edgar Link	pending
eltp-20220630_def.xml	Edgar Link	unprocessable
eltp-20220630_lab.xml	Edgar Link	unprocessable
eltp-20220630_pre.xml	Edgar Link	unprocessable
ex10-3_019.jpg	Edgar Link	pending
ex10-3_020.jpg	Edgar Link	pending
ex10-3_021.jpg	Edgar Link	pending
ex10-3_022.jpg	Edgar Link	pending
ex10-3_023.jpg	Edgar Link	pending
ex10-3_024.jpg	Edgar Link	pending
ex10-3_025.jpg	Edgar Link	pending
ex10-3_026.jpg	Edgar Link	pending
ex10-3_027.jpg	Edgar Link	pending
ex10-3_028.jpg	Edgar Link	pending
ex10-3_029.jpg	Edgar Link	pending
ex10-3_030.jpg	Edgar Link	pending
ex10-3_031.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
eltp-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2022 Q3 Form 10-Q Financial Statement

#000149315222022928 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP ELITE PHARMACEUTICALS INC /NV/ Stock $eltp

2022 Q3 Form 10-Q Financial Statement

#000149315222022928 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTP
ELITE PHARMACEUTICALS INC /NV/ Stock $eltp